Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clearside Biomedical (CLSD)
NASDAQ:CLSD
RESEARCH TOOLSreports
Holding CLSD?
Track your performance easily
CLSD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.65 - $2.12
Previous Close$1.3
Volume124.12K
Average Volume (3M)245.53K
Market Cap
$96.42M
Enterprise Value$68.67M
Total Cash (Recent Filing)$29.36M
Total Debt (Recent Filing)$863.00K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 06, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding74,745,572
10 Day Avg. Volume475,727
30 Day Avg. Volume245,528
Standard Deviation0.29
R-Squared0.17
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.42
Price to Sales (P/S)12.96
Price to Cash Flow (P/CF)-4.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.13
Enterprise Value/Gross Profit8.72
Enterprise Value/Ebitda-2.64
Forecast
1Y Price Target
$5.57Price Target Upside331.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Clearside Biomedical News
Ownership Overview
16.81% Insiders
5.15% Mutual Funds
14.34% Other Institutional Investors
63.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLSD FAQ
What was Clearside Biomedical’s price range in the past 12 months?
Clearside Biomedical lowest stock price was $0.65 and its highest was $2.12 in the past 12 months.
What is Clearside Biomedical’s market cap?
Currently, no data Available
When is Clearside Biomedical’s upcoming earnings report date?
Clearside Biomedical’s upcoming earnings report date is Nov 06, 2024 which is in 48 days.
How were Clearside Biomedical’s earnings last quarter?
Clearside Biomedical released its earnings results on Aug 12, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.136 by $0.036.
Is Clearside Biomedical overvalued?
According to Wall Street analysts Clearside Biomedical’s price is currently Undervalued.
Does Clearside Biomedical pay dividends?
Clearside Biomedical does not currently pay dividends.
What is Clearside Biomedical’s EPS estimate?
Clearside Biomedical’s EPS estimate is -$0.12.
How many shares outstanding does Clearside Biomedical have?
Clearside Biomedical has 74,745,575 shares outstanding.
What happened to Clearside Biomedical’s price movement after its last earnings report?
Clearside Biomedical reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.136. Following the earnings report the stock price went down -0.935%.
Which hedge fund is a major shareholder of Clearside Biomedical?
Among the largest hedge funds holding Clearside Biomedical’s share is Caxton Associates LP. It holds Clearside Biomedical’s shares valued at N/A.
---
Clearside Biomedical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.57 (331.78% Upside)
$5.57 (331.78% Upside)
Blogger Sentiment
Bullish
CLSD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 35.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.40%
Trailing 12-Months
Company Description
Clearside Biomedical
Clearside Biomedical, Inc. is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
---
CLSD Earnings Call
Q1 2024
0:00 / 0:00
---
CLSD Stock 12 Month Forecast
Average Price Target
$5.57
▲(331.78% Upside)
Technical Analysis
Best Analysts Covering CLSD
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+4.28%
reiterated a buy rating 24 days ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +4.28% per trade.
---